Hitomi Yuki

Hitomi Yuki

Auto-generated profile, based on publicly available information

Hitomi Yuki

RIKEN Center for Integrative Medical Sciences, 1-7-22, Suehiro-Cho, Tsurumi-Ku, Yokohama, Kanagawa 230-0045, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
YSYojiro Sakiyama
Yojiro Sakiyama
HYHitomi Yuki
Hitomi Yuki
TMTakashi Moriya
Takashi Moriya
KHKazunari Hattori
Kazunari Hattori
MSMisaki Suzuki
Misaki Suzuki
THTeruki Honma
Teruki Honma

17 April 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YSYoriko Saito
Yoriko Saito
HYHitomi Yuki
Hitomi Yuki
MKMitsuo Kuratani
Mitsuo Kuratani
YHYoshinobu Hashizume
Yoshinobu Hashizume
STShinsuke Takagi
Shinsuke Takagi
FIFumihiko Ishikawa
Fumihiko Ishikawa
Leukemia stem cells (LSCs) that survive conventional chemotherapy are thought to contribute to disease relapse, leading to poor long-term outcomes for patients with acute myeloid leukemia (AML). We previously identified a Src-family kinase (SFK) member, hematopoietic cell kinase (HCK), as a molecular target that is highly differentially expressed in human primary LSCs compared with human normal hematopoietic stem cells (HSCs). We performed a large-scale chemical library screen that integrated a high-throughput enzyme inhibition assay, in silico binding prediction, and crystal structure determination and found a candidate HCK inhibitor, RK-20449, a pyrrolo-pyrimidine derivative with an enzymatic IC50 (half maximal inhibitory concentration) in the subnanomolar range. A crystal structure revealed that RK-20449 bound the activation pocket of HCK. In vivo administration of RK-20449 to nonobese diabetic (NOD)/severe combined immunodeficient (SCID)/IL2rgnull mice engrafted with highly aggressive therapy-resistant AML significantly reduced human LSC and non-stem AML burden. By eliminating chemotherapy-resistant LSCs, RK-20449 may help to prevent relapse and lead to improved patient outcomes in AML.

29 January 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
DTDaisuke Takaya
Daisuke Takaya
CWChiduru Watanabe
Chiduru Watanabe
SNShunpei Nagase
Shunpei Nagase
KKKikuko Kamisaka
Kikuko Kamisaka
YOYoshio Okiyama
Yoshio Okiyama
THTeruki Honma
Teruki Honma
We developed the world’s first web-based public database for the storage, management, and sharing of fragment molecular orbital (FMO) calculation data sets describing the complex interactions between biomacromolecules, named FMO Database (https://drugdesign.riken.jp/FMODB/). Each entry in the database contains relevant background information on how the data was compiled as well as the total energy of each molecular system and interfragment interaction energy (IFIE) and pair interaction energy decomposition analysis (PIEDA) values. Currently, the database contains more than 13 600 FMO calculation data sets, and a comprehensive search function implemented at the front-end. The procedure for selecting target proteins, preprocessing the experimental structures, construction of the database, and details of the database front-end were described. Then, we demonstrated a use of the FMODB by comparing IFIE value distributions of hydrogen bond, ion-pair, and XH/π interactions obtained by FMO method to those by molecular mechanics approach. From the comparison, the statistical analysis of the data provided standard reference values for the three types of interactions that will be useful for determining whether each interaction in a given system is relatively strong or weak compared to the interactions contained within the data in the FMODB. In the final part, we demonstrate the use of the database to examine the contribution of halogen atoms to the binding affinity between human cathepsin L and its inhibitors. We found that the electrostatic term derived by PIEDA greatly correlated with the binding affinities of the halogen containing cathepsin L inhibitors, indicating the importance of QM calculation for quantitative analysis of halogen interactions. Thus, the FMO calculation data in FMODB will be useful for conducting statistical analyses to drug discovery, for conducting molecular recognition studies in structural biology, and for other studies involving quantum mechanics-based interactions.

21 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KOKeiji Ogura
Keiji Ogura
TSTomohiro Sato
Tomohiro Sato
HYHitomi Yuki
Hitomi Yuki
THTeruki Honma
Teruki Honma
Assessing the hERG liability in the early stages of drug discovery programs is important. The recent increase of hERG-related information in public databases enabled various successful applications of machine learning techniques to predict hERG inhibition. However, most of these researches constructed the datasets from only one database, limiting the predictability and scope of the models. In this study, a hERG classification model was constructed using the largest dataset for hERG inhibition built by integrating multiple databases. The integrated dataset consisted of more than 291,000 structurally diverse compounds derived from ChEMBL, GOSTAR, PubChem, and hERGCentral. The prediction model was built by support vector machine (SVM) with descriptor selection based on Non-dominated Sorting Genetic Algorithm-II (NSGA-II) to optimize the descriptor set for maximum prediction performance with the minimal number of descriptors. The SVM classification model using 72 selected descriptors and ECFP_4 structural fingerprints recorded kappa statistics of 0.733 and accuracy of 0.984 for the test set, substantially outperforming the prediction performance of the current commercial applications for hERG prediction. Finally, the applicability domain of the prediction model was assessed based on the molecular similarity between the training set and test set compounds.

6 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTomohiro Sato
Tomohiro Sato
HYHitomi Yuki
Hitomi Yuki
KOKeiji Ogura
Keiji Ogura
THTeruki Honma
Teruki Honma
The inhibition of the hERG potassium channel is closely related to the prolonged QT interval, and thus assessing this risk could greatly facilitate the development of therapeutic compounds and the withdrawal of hazardous marketed drugs. The recent increase in SAR information about hERG inhibitors in public databases has led to many successful applications of machine learning techniques to predict hERG inhibition. However, most of these reports constructed their prediction models based on only one SAR database because the differences in the data format and ontology hindered the integration of the databases. In this study, we curated the hERG-related data in ChEMBL, PubChem, GOSTAR, and hERGCentral, and integrated them into the largest database about hERG inhibition by small molecules. Assessment of structural diversity using Murcko frameworks revealed that the integrated database contains more than twice as many chemical scaffolds for hERG inhibitors than any of the individual databases, and covers 18.2% of the Murcko framework-based chemical space occupied by the compounds in ChEMBL. The database provides the most comprehensive information about hERG inhibitors and will be useful to design safer compounds for drug discovery. The database is freely available at http://drugdesign.riken.jp/hERGdb/.

1 December 2017 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
CWChiduru Watanabe
Chiduru Watanabe
HWHirofumi Watanabe
Hirofumi Watanabe
KFKaori Fukuzawa
Kaori Fukuzawa
LPLorien J. Parker
Lorien J. Parker
YOYoshio Okiyama
Yoshio Okiyama
THTeruki Honma
Teruki Honma